View Older Stories View More Recent Stories
-
STAAR Surgical reaches 4 million ICL sales milestone globally
-
FDA expands EVO ICL age indication to patients 21 to 60 years old
-
STAAR Surgical (STAA) PT Lowered to $19 at Stifel
-
Morgan Stanley Resumes Underweight Rating on STAAR Surgical (STAA)
-
STAAR Surgical (STAA) PT Lowered to $22 at Canaccord Genuity
-
STAAR Surgical adds three board members in cooperation deal
-
Broadwood Partners Comments on STAAR Surgical Shareholders’ Rejection of Proposed Sale to Alcon
-
Needham Reiterates Hold Rating on STAAR Surgical (STAA)
-
BTIG Reiterates Neutral Rating on STAAR Surgical (STAA)
-
STAAR Surgical stockholders reject Alcon merger agreement
-
Broadwood criticizes STAAR Surgical's fourth delay of shareholder vote
-
Alcon exercises right to adjourn STAAR Surgical stockholder meeting
-
Defender Capital opposes STAAR Surgical sale to Alcon ahead of vote
-
Broadwood pledges cooperation with STAAR Surgical after Alcon deal vote
-
STAAR Surgical urges shareholders to approve Alcon's $30.75 per share offer
-
ISS recommends STAAR Surgical deal, but warns shareholders have reason to object
-
Yunqi Capital opposes STAAR merger with Alcon despite revised offer
-
STAAR Surgical gets analyst support for Alcon merger at $30.75 per share
-
Broadwood Partners opposes STAAR Surgical sale to Alcon amid proxy concerns
-
Glass Lewis reaffirms opposition to STAAR Surgical sale to Alcon
-
STAAR Surgical defends merger process amid activist criticism
-
Broadwood opposes revised STAAR Surgical-Alcon deal, cites board dissent
-
Yunqi Capital opposes STAAR Surgical merger despite Alcon's raised bid
-
STAAR Surgical (STAA) PT Raised to $30.75 at Wells Fargo
-
Alcon bumps STAAR Surgical bid to $30.75, but Broadwood remains vehemently against
-
Broadwood opposes revised STAAR Surgical acquisition by Alcon
-
STAAR Surgical (STAA) PT Raised to $30.75 at Canaccord Genuity
-
Alcon raises STAAR acquisition price to $30.75 per share
-
Broadwood Partners maintains opposition to STAAR Surgical sale to Alcon
-
Egan-Jones reaffirms vote against STAAR Surgical sale to Alcon
-
STAAR Surgical's go-shop period expires with no competing bids
-
Broadwood reiterates push for STAAR Surgical board shake-up as Alcon vote nears
-
Broadwood Partners seeks to remove three STAAR Surgical directors
-
STAAR Surgical reveals board dissent over amended Alcon deal ahead of vote
-
Exclusive: Broadwood says Alcon's earnings reveal STAAR bid came from 'weakness'
-
Broadwood calls for new directors at STAAR Surgical for go-shop oversight
-
STAAR Surgical amends Alcon merger deal to allow 30-day bidding period
-
Yunqi Capital urges STAAR shareholders to reject Alcon merger after Q3 results
-
STAAR Surgical (STAA) Reports In-Line Q3 EPS
-
Alcon, Broadwood trade blows in fight for STAAR Surgical's future
-
Broadwood opposes Alcon's STAAR Surgical acquisition bid
-
Yunqi Capital calls for termination of STAAR-Alcon merger deal
-
Alcon rejects raised bid for STAAR Surgical as shareholders revolt
-
STAAR Surgical postpones shareholder vote on Alcon merger to December
-
Yunqi Capital urges STAAR Surgical to end Alcon merger deal
-
Exclusive: Roughly 72% of STAAR shares oppose Alcon deal, vote delayed
-
Broadwood seeks to remove STAAR Surgical directors after vote delay
-
STAAR postpones stockholder meeting on Alcon merger to November
-
Canaccord Genuity Reiterates Hold Rating on STAAR Surgical (STAA)
-
Yunqi Capital issues new letter to STAAR Surgical (STAA) Board

